December 9, 2020

Sirtex Medical Makes Strategic Investment in BlackSwan Vascular

December 9, 2020—Sirtex Medical announced a strategic investment in BlackSwan Vascular, Inc., a company developing therapies for endovascular embolization. BlackSwan Vascular is a private company founded in 2017 and based in Hayward, California.

According to Sirtex, the investment provides resources for further development of BlackSwan Lava, a liquid embolic system specifically tailored for peripheral vascular target indications. The investment will support clinical trials for potential FDA approval for this indication. Lava includes optimized radiopacity, availability in two viscosities, reduced preparation time, controlled delivery, and the ability to enable treatment for a wide array of peripheral vascular diseases.

Under the collaboration, Sirtex made a significant equity investment in exchange for preferred shares in BlackSwan as well as an option to purchase the remaining shares of the company at an agreed price. In addition, Sirtex will appoint an observer member to the Board of Directors.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

December 9, 2020

Sirtex Medical Makes Strategic Investment in BlackSwan Vascular

Current Issue

Keep In Touch